Literature DB >> 26546407

New Insights into Eosinophilic Otitis Media.

Hiromi Kanazawa1, Naohiro Yoshida2, Yukiko Iino3.   

Abstract

Eosinophilic otitis media (EOM) is a type of intractable otitis media that occurs mainly in patients with bronchial asthma (BA). In 2011, the diagnostic criteria for EOM were established. EOM is characterized by the presence of a highly viscous yellowish effusion containing eosinophils and immunoglobulin E (IgE), eosinophil chemoattractants, such as eosinophil cationic protein, interleukin-5, and eotaxin. Local sensitization against foreign agents such as fungi or bacteria (e.g., Staphylococcus aureus) may result in local IgE production in the middle ear and may be responsible for the severity of EOM. The clinical features of EOM closely resemble localized eosinophilic granulomatosis polyangiitis, therefore it is necessary to be vigilant to the symptoms of mononeuritis, polyneuritis, and skin purpura during diagnosis. Standard treatment for EOM is the instillation of triamcinolone acetonide into the mesotympanum. However, severe cases exhibiting strong inflammation and otorrhea are not easily controlled with antibiotics and/or corticosteroids. We proposed the introduction of a severity score to evaluate the severity of EOM. This score correlated with local IgE levels in middle ear effusion. Clinically, the risk factors associated with this severity score were body mass index, and the duration of bronchial asthma (from the onset of BA to the age of the first consultation of otitis media to our hospital). We emphasize that early diagnosis and adequate treatment are vital in preventing progressive and sudden hearing loss resulting from EOM.

Entities:  

Keywords:  Bronchial asthma; Eosinophilic chronic rhinosinusitis; Eosinophilic otitis media; Immunoglobulin E; Severity score; Viscous middle ear effusion

Mesh:

Substances:

Year:  2015        PMID: 26546407     DOI: 10.1007/s11882-015-0577-2

Source DB:  PubMed          Journal:  Curr Allergy Asthma Rep        ISSN: 1529-7322            Impact factor:   4.806


  37 in total

1.  IL-33-responsive innate lymphoid cells are an important source of IL-13 in chronic rhinosinusitis with nasal polyps.

Authors:  Joanne L Shaw; Samer Fakhri; Martin J Citardi; Paul C Porter; David B Corry; Farrah Kheradmand; Yong-Jun Liu; Amber Luong
Journal:  Am J Respir Crit Care Med       Date:  2013-08-15       Impact factor: 21.405

2.  Eosinophilic otitis media.

Authors:  Adrienne L Childers; Judah Gruen; Sadia Sayeed; Celeste N Powers; Daniel H Coelho
Journal:  Otol Neurotol       Date:  2014-07       Impact factor: 2.311

3.  Antigen-specific IgE in middle ear effusion of patients with eosinophilic otitis media.

Authors:  Hiromi Kanazawa; Naohiro Yoshida; Akihiro Shinnabe; Yukiko Iino
Journal:  Ann Allergy Asthma Immunol       Date:  2014-05-24       Impact factor: 6.347

4.  Association between group 2 innate lymphoid cells enrichment, nasal polyps and allergy in chronic rhinosinusitis.

Authors:  D Miljkovic; A Bassiouni; C Cooksley; J Ou; E Hauben; P-J Wormald; S Vreugde
Journal:  Allergy       Date:  2014-06-13       Impact factor: 13.146

5.  Cochlear implantation in patients with chronic otitis media.

Authors:  Hiromi Kojima; Yuika Sakurai; Masahiro Rikitake; Yasuhiro Tanaka; Atsushi Kawano; Hiroshi Moriyama
Journal:  Auris Nasus Larynx       Date:  2010-02-26       Impact factor: 1.863

6.  Diagnostic criteria of eosinophilic otitis media, a newly recognized middle ear disease.

Authors:  Yukiko Iino; Sachiko Tomioka-Matsutani; Atsushi Matsubara; Takashi Nakagawa; Manabu Nonaka
Journal:  Auris Nasus Larynx       Date:  2011-01-19       Impact factor: 1.863

7.  Eosinophil chemoattractants in the middle ear of patients with eosinophilic otitis media.

Authors:  Y Iino; K Kakizaki; H Katano; H Saigusa; S Kanegasaki
Journal:  Clin Exp Allergy       Date:  2005-10       Impact factor: 5.018

8.  IL-5 and eotaxin levels in middle ear effusion and blood from asthmatics with otitis media with effusion.

Authors:  Manabu Nonaka; Akira Fukumoto; Chika Ozu; Eriko Mokuno; Shunkichi Baba; Ruby Pawankar; Toshiaki Yagi
Journal:  Acta Otolaryngol       Date:  2003-04       Impact factor: 1.494

Review 9.  Eosinophilic otitis media: CT and MRI findings and literature review.

Authors:  Won Jung Chung; Jeong Hyun Lee; Hyun Kyung Lim; Tae Hyun Yoon; Kyung Ja Cho; Jung Hwan Baek
Journal:  Korean J Radiol       Date:  2012-04-17       Impact factor: 3.500

10.  A Case of Severe Asthma with Eosinophilic Otitis Media Successfully Treated with Anti-IgE Monoclonal Antibody Omalizumab.

Authors:  Azusa Okude; Etsuko Tagaya; Mitsuko Kondo; Manabu Nonaka; Jun Tamaoki
Journal:  Case Rep Pulmonol       Date:  2012-11-25
View more
  5 in total

Review 1.  Idiopathic, Infectious and Reactive Lesions of the Ear and Temporal Bone.

Authors:  Kelly R Magliocca; Esther X Vivas; Christopher C Griffith
Journal:  Head Neck Pathol       Date:  2018-08-01

2.  Sequential Biotherapy Targeting IL-5 and IL-4/13 in Patients with Eosinophilic Asthma with Sinusitis and Otitis Media.

Authors:  Ayumi Chikumoto; Keiji Oishi; Kazuki Hamada; Tsunahiko Hirano; Tomoyuki Kakugawa; Keiko Kanesada; Kazuto Matsunaga
Journal:  Biomolecules       Date:  2022-03-30

Review 3.  Personalized Medicine in Allergy.

Authors:  Matteo Ferrando; Diego Bagnasco; Gilda Varricchi; Stefano Bernardi; Alice Bragantini; Giovanni Passalacqua; Giorgio Walter Canonica
Journal:  Allergy Asthma Immunol Res       Date:  2017-01       Impact factor: 5.764

4.  Successful treatment of eosinophilic chronic rhinosinusitis and eosinophilic otitis media using the anti-IL-5 receptor monoclonal antibody benralizumab: A case report.

Authors:  Hiroki Kagoshima; Ryusuke Hori; Tsuyoshi Kojima; Yusuke Okanoue; Atsushi Taguchi; Hirotaka Yamamoto; Koki Hasebe; Kazuhiko Shoji
Journal:  Respir Med Case Rep       Date:  2020-06-17

5.  Is otitis media with effusion associated with Samter's triad a new nosological entity? A preliminary report on inflammatory mediator production.

Authors:  Ljiljana Čvorović; Aleksandar Trivić; Zoran Dudvarski; Ana Jotić; Miljan Folić; Nenad Arsović; Zoran Bukumirić; Uglješa Grgurević; Danilo Vojvodić; Aleksandar Perić
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-08-12       Impact factor: 2.503

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.